| English |
|---|
| Title | The Toxicologic Evaluation of Radio-Pharmaceuticals |
|---|
| Subtitle | |
|---|
| Authors | JONATHAN P.MILLER, L.E.MICHAEL CRAWFORD |
|---|
| Authors(kana) | |
|---|
| Organization | Radio-Pharmaceuticals Research Department, Abbott Laboratories |
|---|
| Journal | The Japanese Journal of nuclear medicine |
|---|
| Volume | 6 |
|---|
| Number | 3 |
|---|
| Page | 213-216 |
|---|
| Year/Month | 1969/9 |
|---|
| Article | Report |
|---|
| Publisher | THE JAPANESE SOCIETY OF NUCLEAR MEDICINE |
|---|
| Abstract | In considering the potential toxicity of radio-pharmaceuticals, both chemical toxicity and radiation effects must be evaluated. Most modern radio-pharmaceuticals utilize "tracer" techniques and the mass administered is so minute that pharmacologic response is difficult to detect. Radio-Pharmaceutical agents are usually administered on a "single-dose" basis and they are not intended for chronic administration. Typical administered doses of various radio-pharmaceuticals are summarized in Table I. The small administered mass is directly related to the large safety factors established for radio-pharmaceuticals. Table II summarizes calculated factors based on typical doses to man and acute intravenous toxicity studies in mice. Because of physical decay of the radionuclide, the required injection volume must increase with time in order to administer a given amount of radioactivity. This decay factor can be significant with pharmacologically-active compounds labeled with short-lived nuclides; e.g., Chlormerodrin Hg 197. |
|---|
| Practice | Clinical medicine |
|---|
| Keywords | |
|---|